[Private prescriptions of hypnotics and tranquilizers for statutory health-insured patients: regulatory framework versus reality of primary care].
Arzneimittelkommission der Deutschen Apotheker (AMK), Berlin.
Martin
M
Schulz
D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D053961:Azabicyclo Compounds / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D003284:Contract Services / Q000331:legislation & jurisprudence; D003299:Cooperative Behavior; D004363:Drug Utilization; D005858:Germany; D019983:Guideline Adherence / Q000331:legislation & jurisprudence; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D007049:Iatrogenic Disease; D007348:Insurance, Health / Q000331:legislation & jurisprudence*; D007356:Insurance, Pharmaceutical Services / Q000331:legislation & jurisprudence*; D033183:Interdisciplinary Communication; D008134:Long-Term Care / Q000331:legislation & jurisprudence; D009313:National Health Programs / Q000331:legislation & jurisprudence*; D056687:Off-Label Use / Q000331:legislation & jurisprudence; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000331:legislation & jurisprudence*; D011320:Primary Health Care / Q000331:legislation & jurisprudence*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000209:etiology / Q000517:prevention & control; D000077334:Zolpidem
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; D011725:Pyridines; C515050:zopiclone; D001569:Benzodiazepines; D000077334:Zolpidem